New Gout Drug May Help Lower Serum Urate Levels
A new medication could help adults with gout reach target urate levels to prevent joint and tissue damage.
Updated on Oct. 29, 2026 in Arthritis
Live Poll
Do you trust that new medical innovations are effectively improving treatment options for chronic conditions?
Data from the phase 3 REDUCE-2 study shows that the experimental drug pozdeutinurad significantly lowers serum urate in people with gout. These findings, presented at ACR Convergence 2026 on November 11, 2026, suggest a potential new way for patients to manage chronic urate levels.
Why it matters
Uncontrolled gout requires effective reduction of serum urate to prevent long-term damage to joints and surrounding tissues. New therapeutic options are needed to help patients achieve and maintain target urate levels to avoid these complications.
The Phase 3 REDUCE-2 trial enrolled 811 patients in a 12-month double-blind, randomized, placebo-controlled study. Researchers found significant reductions in serum urate levels for those on daily oral doses of 50 mg or 75 mg of pozdeutinurad compared to placebo.
The players
Sobi
A pharmaceutical company focused on developing specialized treatments for rare diseases and inflammatory conditions.
ACR Convergence 2026
The annual meeting of the American College of Rheumatology, which showcases the latest research in arthritis and autoimmune diseases.
The details
Pozdeutinurad is an oral medication designed to lower serum urate, a compound that crystallizes in joints to cause gout. By facilitating the reduction of urate below the 6 mg/dL threshold, the drug aims to mitigate the risk of tissue damage. The study maintained consistency across groups, with similar rates of treatment-emergent adverse events reported in both the 50 mg (61.7%) and 75 mg (60.7%) arms as in the placebo group (60.9%).
Timeline
November 11, 2026: Late-breaking data presented at ACR Convergence 2026.
Month 6: Primary endpoint assessment for serum urate levels.
Month 12: End of the clinical study data collection period.
Health Landscape
This study contributes to the evolving standards of care for gout, which centers on maintaining serum urate below 6 mg/dL. Pozdeutinurad represents a potential addition to the existing landscape of urate-lowering therapies aimed at long-term disease management.
If you are managing gout, these findings highlight the clinical goal of maintaining serum urate levels below 6 mg/dL to protect joint health. It is worth discussing current treatment targets and the availability of new therapeutic options with your physician.
The takeaway
Achieving and maintaining low serum urate levels is key to preventing the joint damage associated with chronic gout. Speak with your doctor about your current urate levels and whether your long-term treatment plan effectively manages your risk of flare-ups.
Further reading
Learn more about the latest research and management strategies in our Arthritis section.
Source note: This article includes information reported by Firstwordpharma.
Live Poll
Do you trust that new medical innovations are effectively improving treatment options for chronic conditions?
